Angiotensin II in Cell Growth and Matrix Production

  • Willa A. Hsueh
  • Yung S. Do
  • Pamela W. Anderson
  • Ronald E. Law
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 377)


The functions of angiotensin II (AII) in vasconstriction, stimulation of adrenal aldosterone secretion and renal proximal tubular sodium reabsorption are well known, but AII’s role in growth in cardiovascular and renal systems is only recently recognized (1,2). This growth effect has a number of potential pathological implications. AII induces hypertrophy of mesangial cells (3), which may directly contribute to the development of glomerulosclerosis, the hallmark pathological change associated with diabetic nephropathy (4). AII also induces hypertrophy of adult vascular smooth muscle cells which may contribute to vascular remodeling processes following injury (5–7). In the heart, AII has direct effects on the cardiac fibroblasts and possibly the cardiomyocytes, which may contribute to the development of left ventricular hypertrophy and cardiac remodeling (8–11). In order to define the cellular mechanism of AII action in these processes, we studied the effect of AII in cultured mesangial cells and in cardiac fibroblasts and AII’s potential interaction with other growth factors on the cells. In addition to growth, we also found that AII has direct effects on matrix production which further contributes to remodelling in these tissues. In this context, also see the chapter by Wolf elsewhere in this volume.


Left Ventricular Hypertrophy Mesangial Cell Receptor mRNA Cardiac Fibroblast Experimental Myocardial Infarction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Peach MJ, 1977. Renin-angiotensin system: Biochemistry and mechanism of action. Physiol Rev; 57: 313–370.PubMedGoogle Scholar
  2. 2.
    Hsueh WA, 1992. The role of the extrarenal renin-angiotensin system. Current Opinion in Cardiology; 7: 745–751.CrossRefGoogle Scholar
  3. 3.
    Anderson PW, Do YS, Hsueh WA, 1993. Angiotensin II causes mesangial cell hypertrophy. Hypertension; 21: 29–35.PubMedCrossRefGoogle Scholar
  4. 4.
    Steffes MW, Osterby R, Chavers B, Mauer SM, 1989. Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes; 38: 1077–1081.PubMedCrossRefGoogle Scholar
  5. 5.
    Geisterfer AAT, Peach MJ, Owens GK, 1988. Angiotensin II induces hypertrophy, not hyperplasia, of cultured smooth muscle cells. Circ Res; 62: 749–756.PubMedCrossRefGoogle Scholar
  6. 6.
    Naftilan AJ, Pratt RE, Dzau VJ, 1989. Induction of PDGF A-chain and c-myc gene expression by Ang II in cultured vascular smooth cells. J Clin Invest; 83: 141–142.CrossRefGoogle Scholar
  7. 7.
    Schwartz SM, Campbell GR, Campbell JH, 1986. Replication of smooth muscle cells in vascular disease. Circ Res 58: 427–444.PubMedCrossRefGoogle Scholar
  8. 8.
    Villarreal FJ, Kim NN, Ungab GD, Printz MP, Killmann WH, 1993. Identification of functional angiotensin II receptor on rat cardiac fibroblasts. Circulation; 88: 2849–2861.PubMedCrossRefGoogle Scholar
  9. 9.
    Iwami K, Ashizawa N, Do YS, Hsueh WA, 1994. Regulation of angiotensin II AT1 receptor mRNA and its function in rat cardiac fibroblasts. In press.Google Scholar
  10. 10.
    Sadoshima J, Izumo S, 1993. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical Role of the AT1 Subtype. Circulation Res; 73: 413–423.PubMedCrossRefGoogle Scholar
  11. 11.
    Schorb W, Booz GW, Dostal DE, Conrad KM, Chang KC, Baker KM, 1993. Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts. Cir Res; 72: 1245–1254.CrossRefGoogle Scholar
  12. 12.
    Froelick ED, Chobanian AV, Devereux RB, Dustan HP, Fauad-Tarazi F, Horan MJ, Marcus M, Pfeffer MA, Re RN, Rocella EJ, Savage D, Shub C, 1992. The heart in hypertension. N Engl J Med; 327: 998–1008.CrossRefGoogle Scholar
  13. 13.
    Linz W, Schoelkens BA, Ganten D, 1989. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens; 11: 1325–1350.CrossRefGoogle Scholar
  14. 14.
    Pfeffer MA, Gervasio AL, Vaughan DE, Parisi AF, Braunwald E, 1988. Effect of captopril on progressive ventricular dilation after anterior myocardial infarction. N Engl J Med; 319: 80–86.PubMedCrossRefGoogle Scholar
  15. 15.
    Pferrer MA, Braunwald E, Moya LA, Basta L, Brown Jr EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, 1992. Effect of captopril on mortality and morbidity in patients with left ventricular dysfuncion after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Ivestigators. N Engl J Med; 327:669.CrossRefGoogle Scholar
  16. 16.
    Dahloef B, Pennert K, Hansson L, 1992. Reversal of left ventricular hypertrophy in hypertensive patients. A meta analysis of 109 treatment studies. Am J Hypertens; 5: 95–110.Google Scholar
  17. 17.
    Morton JJ, Beattie EC, MacPherson F, November, 1993. Differential effects of captopril and the angiotensin receptor antagonist DuP753 on cardiovascular remodelling in the spontaneously hypertensive rat (SHR). A1235. American Heart Assn Meeting.Google Scholar
  18. 18.
    Bishopric HN, Simpson PC, Ordahl CP, 1987. Induction of the skeletal α-actin gene in α1-adrenoceptor-mediated hypertrophy of rat cardiac myocytes. J Clin Invest 80: 1194–1199.PubMedCrossRefGoogle Scholar
  19. 19.
    Wittenberg BA, Robinson TF, 1986. Oxygen requirements, morphology, cell coat, and membrane permeability of calcium-tolerant moycytes from heart of adult rats. Cell Tissue Res; 216: 231–215.Google Scholar
  20. 20.
    Mamuya WS, Brecher P, 1992. Fibronectin expression in the normal and hypertrophic rat heart. J Clin Invest; 89: 392–401.PubMedCrossRefGoogle Scholar
  21. 21.
    Mamuya W, Chobanian A, Brecher P, 1992. Age-related changes in fibronectin expression in spontaneously hypertensive, wistar-kyoto, and wistar rat hearts. Circ Res; 71: 1341–1350.PubMedCrossRefGoogle Scholar
  22. 22.
    Shekhonin BV, Curiev SB, Irgashev SB, Koteliansky VE, 1990. Immunofluorescent identification of fibronectin and fibrinogen/fibrin in experimental myocardial infarction. Cell Cardiol; 22: 533–541.CrossRefGoogle Scholar
  23. 23.
    Casscells W, Kimura H, Sanchez JA, Yu Z-X, Ferrans VJ, 1990. Immunohistochemical study of fibronectin in experimental myocardial infarction. Am J Pathol 137: 801–810.PubMedGoogle Scholar
  24. 24.
    Crawford DC, Chobanian AV, Brecher P, 1994. Angiotensin II induces fibronectin expression associated with cardiac fibrosis in the rat. Cir Res; 74: 727–739.CrossRefGoogle Scholar
  25. 25.
    Killery P, Marquat FX, Borel JP, 1990. Fibronectin dependence of the contraction of collagen by human skin fibroblasts. Exp Cell Res 67: 787–794.Google Scholar
  26. 26.
    Herdin A, Bottger BA, Forsberg E, Johansson S, Thyberg J, 1988. Diverse effects of fibronectin and laminin on phenotypic properties of cultured arterial smooth muscle cells. Cell Biology; 107: 307–319.CrossRefGoogle Scholar
  27. 27.
    Weber KT, Brilla CG, 1991. Pathological hypertrophy and cardiac interstitium. Circ; 83: 1849–1865.CrossRefGoogle Scholar
  28. 28.
    Matsubara H, Kanasaki M, Murasawa S, Tsukaguchi Y, Nio Y, Inada M, 1994. Differential gene expression and regulation of angiotensin II receptor subtypes in rat cardiac fibroblasts and cariomyocytes in culture. J Clin Invest; 93: 1592–1601.PubMedCrossRefGoogle Scholar
  29. 29.
    Long CS, Henrich CJ, Simpson PC, 1991. A growth factor for cardiac myocytes is produced by cardiac nonmyocytes. Cell Reg; 2: 1081–1095.Google Scholar
  30. 30.
    Mukoyama M, Nakajima M, Horuchi M, Sasamura H, Pratt R, Dzau VJ, 1993. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem; 268: 24539–24542.PubMedGoogle Scholar
  31. 31.
    Kambayashi Y, Bardhan S, Takahashi K, Tsuzuki S, Inui H, Hamakubo T, Inagami T, 1993. Molecular cloning of novel angiotensin II receptotr isoform involved in phosphotyrosine phosphatase inhibition. 268:24543–245646.Google Scholar
  32. 32.
    Grady EF, Sechi LA, Griffin CA, Schambelan M, Kalinyak JE, 1991. Expression of the type 2 angiotensin receptor in the developing rat fetus. J Clin Invest 88: 921–933.PubMedCrossRefGoogle Scholar
  33. 33.
    Sechi LA, Griffin CA, Grady EF, Kalinyak JE, Schambelan M, 1992. Characterization of angiotensin II receptor subtypes in rat heart. Circ Res; 71: 1482–1489.PubMedCrossRefGoogle Scholar
  34. 34.
    Nadal-Ginard B, Mahdavi V, 1989. Molecular basis of cardiac performance. Plasticity of the myocardium generated through protein isoform switches. J Clin Invest 84: 1693–1700.PubMedCrossRefGoogle Scholar
  35. 35.
    Gellman DD, Pirani CI, Soothill JF, Muehrcke RC, Kark RM, 1989. Diabetic nephropathy: a clinical and pathologic study based on renal biopsies. Medicine; 38:321.Google Scholar
  36. 36.
    Keane WF, Anderson S, Aurell M, DeAeeuw D, Narins RG, Povar G, 1989. Angiotensin-converting enzyme inhibitors and progressive renal insufficiently: current experience and future directions. Ann Intern Med; 111: 503–516.PubMedCrossRefGoogle Scholar
  37. 37.
    Anderson S, Brenner BM, 1988. Pathogenesis of diabetic glomerulopathy: hemodynamic considerations. Diabetes Metab Rev; 4: 163–177.PubMedCrossRefGoogle Scholar
  38. 38.
    Schultz PJ, Schorer AE, Raij L, 1990. Effects of endothelium-derived relaxing factor and nitric oxide on rat mesangial cells. Am J Physiol; 258:F162–F167.Google Scholar
  39. 39.
    Mene P, Simonson MS, Dunn MJ, 1989. Physiology of the mesangial cell. Physiol Rev; 69: 1347–1424.PubMedGoogle Scholar
  40. 40.
    Riser BL, Cortes P, Znac X, Bernstien J, Dumler F, Narrins RG, 1992. Intraglomerular pressure and mesangial streching stimulate extracellular matrix formation in the rat. J Clin Invest; 90: 1932–1943.PubMedCrossRefGoogle Scholar
  41. 41.
    Wolf G, Haberstroh U, Neilson EG, 1992. Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am J Pathol; 140: 95–107.PubMedGoogle Scholar
  42. 42.
    Ray PE, Agulera G, Kipp JB, Horikoshi S, Klotman PE, 1992. Angiotensin II receptor-mediated proliferation of cultured human fetal mesangial cells. Am J Pathol; 140: 95–107.Google Scholar
  43. 43.
    Anderson PW, Zhang XY, Law RE, Hsueh WA, 1994. The effect of angiotensin II on TGF-βl, protooncogene and extracellular matrix gene expression in mesangial cells. Presented at ASN Annual Meeting.Google Scholar
  44. 44.
    Kagami S, Border WA, Miller DE, Noble NA, 1994. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest; 93: 2431–2437.PubMedCrossRefGoogle Scholar
  45. 45.
    Gaber L, Walton C, Brown S, Bakris G, 1994. Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. In press.Google Scholar
  46. 46.
    Taguma Y, Kitamoto Y, Futaki G, Ueda H. Monma H, Ishizaki M, Takahashi H, Sekino H, Sasaki Y, 1985. Effect of captopril in heavy proteinuria in azomatic diabetics. N Engl J Med; 313: 1617–1620.PubMedCrossRefGoogle Scholar
  47. 47.
    Marre M, Chatellier G, Leblanc H, Guyene TT, Menard J, Passa P, 1988. Prevention of diabetic nephropathy with enalapril in normotensive diabetic with microalbuminuria. BMJ; 297: 1092–1095.PubMedCrossRefGoogle Scholar
  48. 48.
    Mathiesen ER, Hommel E, Giese J, Parving HH, 1991. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ; 303: 81–87.PubMedCrossRefGoogle Scholar
  49. 49.
    Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, 1993. The effect of angiotensin-converting enzyme inhibition on diabetic nephriopathy. N Engl J Med; 329: 1456–1462.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • Willa A. Hsueh
    • 1
  • Yung S. Do
    • 1
  • Pamela W. Anderson
    • 1
  • Ronald E. Law
    • 1
  1. 1.Department of Medicine, Division of Endocrinology, Diabetes and HypertensionUniversity of Southern California, School of MedicineLos AngelesUSA

Personalised recommendations